| Outcome Measures: |
Primary: The primary endpoint is based upon the percentage of CD4+T regulatory (defined as CD3+CD4+CD25highCD127low) cells within the CD3+CD4+T cell gate following treatment with IL-2., Fluorescence-activated cell sorting assay, From Day 0 to Day 60 | Secondary: T regulatory cell phenotype and stability, Fluorescence-activated cell sorting assay, From Day 0 to Day 60|T effector cell number and phenotype, Fluorescence-activated cell sorting assay, From Day 0 - Day 60|T cell subset proliferation and populations, Fluorescence-activated cell sorting assay, From Day 0 - Day 60|Intracellular T cell and natural killer(NK) cell signalling, Fluorescence-activated cell sorting assay, From Day 0 - Day 60|T regulatory cell function, T suppression assay, From Day 0 - Day 60|IL-2 pathway genotype, DNA sequencing, From Day 0 - Day 60|Lymphocyte Subsets, Complete blood count, From Day 0 to Day 60|Serum Cytokines, Enzyme-linked immuno sorbent assay, From Day 0 to Day 60|Glycaemic control, Self monitoring blood glucose readings, HbA1c, insulin usage, From Day 0 to Day 60|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, From Day O to Day 60
|
